186405-37-8

Usage

Uses

Used in Pharmaceutical Industry:
(4-Trifluoromethylbenzenesulfonyl)acetonitrile is used as a building block in organic synthesis for the production of various active pharmaceutical ingredients and drug candidates. Its versatile reactivity allows for the creation of a wide range of compounds with potential therapeutic applications.
Used in Materials Science:
(4-Trifluoromethylbenzenesulfonyl)acetonitrile has been studied for its potential application in materials science, where its unique properties may contribute to the development of new materials with specific characteristics.
Used as a Reagent in Chemical Analysis and Synthesis:
(4-Trifluoromethylbenzenesulfonyl)acetonitrile serves as a reagent in chemical analysis and synthesis, facilitating various chemical reactions and processes in research and industrial settings.

InChI:InChI=1/C9H6F3NO2S/c10-9(11,12)7-1-3-8(4-2-7)16(14,15)6-5-13/h1-4H,6H2

Upstream product

• 1230154-76-3 C₉H₆F₃NS 
• 825-83-2 4-trifluoromethylbenzenethiol 
• 1624363-23-0 3-azido-2-methylbut-3-en-2-ol 
• 455-13-0 4-Iodobenzotrifluoride 

Downstream Products

• 1260149-74-3 1-phenyl-2-((4-(trifluoromethyl)phenyl)sulfonyl)ethan-1-one 
• 1383563-61-8 thiophen-2-ylmethyl-[3-[(4-trifluoromethylbenzenesulfonyl)]thieno[2,3-e][1,2,3]triazolo[1,5-a]pyrimidin-5-yl]amine 
• 1383563-55-0 3-(4-trifluoromethylbenzenesulfonyl)-4H-thieno[2,3-e]-[1,2,3]triazolo[1,5-a]pyrimidin-5-one 

Relevant academic research and scientific papers

A Concise Route to 2-Sulfonylacetonitriles from Sodium Metabisulfite

A three-component reaction of aryldiazonium tetrafluoroborates, sodium metabisulfite, and 3-azido-2-methylbut-3-en-2-ol under mild conditions is described. By using abundant and cheap sodium metabisulfite as the sulfur dioxide surrogate, this protocol features good functional group compatibility, affording 2-arylsulfonylacetonitriles in moderate to good yields. The reaction proceeds smoothly at room temperature without the need of any catalysts or additives. Moreover, the synthetic utility of this method is demonstrated by the transformation of 2-arylsulfonylacetonitrile into 2-arylsulfonyl acetamide and 2-arylsulfonylethylamine. (Figure presented.).

Photoinduced synthesis of 2-sulfonylacetonitriles with the insertion of sulfur dioxide under ultraviolet irradiation

Metal-free insertion of sulfur dioxide with aryl iodides and 3-azido-2-methylbut-3-en-2-ol under ultraviolet irradiation at room temperature is achieved, giving rise to 2-(arylsulfonyl)acetonitriles in moderate to good yields. Alkyl iodide is also workable under these conditions. This transformation proceeds smoothly under mild conditions with a broad substrate scope. Various functional groups are compatible including amino, ester, halo, and trifluoromethyl groups. No metal catalyst or additive is needed during the reaction process. Mechanistic studies show that under ultraviolet irradiation, an aryl radical is generated in situ from aryl iodide, which undergoes subsequent sulfonylation via the insertion of sulfur dioxide leading to arylsulfonyl radical intermediates. Then the arylsulfonyl radical reacts with 3-azido-2-methylbut-3-en-2-ol giving rise to the corresponding 2-(arylsulfonyl)acetonitrile.

3-(PHENYLSULFONYL)-[1,2,3]TRIAZOLO[1,5A]QUINAZOLIN-5(4H)-ONE DERIVATIVES

The present invention relates to a compound according to formula (I), wherein R1 and R5 are independently selected from H, halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, -Cn-alkyl-N(R12)(R13) with n=0-3, -Cn-alkyl-C(O)N(R12)(R13) with n=0-3, -SO2-N(R14)-C(O)-R15; -Cn-alkyl-N(R14)-C(O)-R15 with n=0-3, -Cn-alkyl-C(O)-OR16 with n=0-3, -O(C1-C3-alkyl-O)m-C1-C3-alkyl-OR10 with m=0-3, -Cn-alkyl-OR16 with n=0-3, -NH-Cn-alkyl-R18 with n=0-3; -O-Cn-alkyl-R18 with n=0-3; -OPO(OR10)2, -PO(OR10)2, and a heterocycle optionally substituted by one or more R17; R3 is selected from halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, -Cn-alkyl-N(R12)(R13) with n=0-3, -Cn-alkyl-C(O)N(R12)(R13) with n=0-3, -SO2-N(R14)-C(O)-R15; -Cn-alkyl-N(R14)-C(O)-R15 with n=0-3, -Cn-alkyl-C(O)-OR16 with n=0-3, -O(C1-C3-alkyl-O)m-C1-C3-alkyl-OR10 with m=0-3, -Cn-alkyl-OR16 with n=0-3, -NH-Cn-alkyl-R18 with n=0-3; -O-Cn-alkyl-R18 with n=0-3; -OPO(OR10)2, -PO(OR10)2, and a heterocycle optionally substituted by one or more R17; R2 and R4 are independently selected from H, halogen, C1-C6-alkyl optionally substituted by one or more R11; R6, R7, R8 and R9 are independently selected from H, halogen, hydroxyl, NO2, CN, C1-C6-alkyl optionally substituted by one or more R11, C1-C6-alkoxy optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, -Cn-alkyl-N(R12)(R13) with n=0-3, -Cn-alkyl-C(O)N(R12)(R13) with n=0-3, -SO2-N(R12)(R13), -SO2-N(R14)-C(O)-R15; -Cn-alkyl-N(R14)-C(O)-R15 with n=0-3, -Cn-alkyl-C(O)-OR16 with n=0-3, -O(C1-C3-alkyl-O)m-C1-C3-alkyl-OR10 with m=0-3, -Cn-alkyl-OR16 with n=0-3, -NH-Cn-alkyl-R18 with n=0-3; -O-Cn-alkyl-R18 with n=0-3; -OPO(OR10)2, -PO(OR10)2, and a heterocycle optionally substituted by one or more R17; R10 is selected from H and C1-C6-alkyl optionally substituted by one or more R11; said one or more R11 is independently selected from Cl, F and hydroxy; R12, R13, R14, R15 and R16 are independently selected from H, C1-C6-alkyl optionally substituted by one or more R11, C3-C6-cycloalkyl optionally substituted by one or more R11, -SO2-C1-C6-alkyl optionally substituted by one or more R11, or wherein said R12 and R13 together with the nitrogen to which they are attached form a heterocycle optionally substituted by one or more R17; said one or more R17 is independently selected from halogen, hydroxy, NO2, CN, -N(R12)(R13), -C(O)-R16, -C(O)-OR16, -Cn-alkyl-OR16 with n=0-3, C1-C6-alkyl optionally substituted by one or more R11, and C1-C6-alkoxy optionally substituted by one or more R11; R18 is selected from -N(R12)(R13), -OR10, -C(O)-R16, -C(O)-OR16, -C(O)- N(R12)(R13), CN, and a heterocycle optionally substituted by one or more R17; and wherein at least one of R1, R2, R4, R5, R6, R7, R8 or R9 is not H; and pharmaceutically acceptable salts, stereoisomers, enantiomers, tautomers of the compounds of formula (I) as well as pharmaceutical compositions thereof and their uses in methods of reducing the virulence of bacteria that express AgrA, in methods for preventing or treating diseases caused or exacerbated by bacteria, preferably by Staphylococcus aureus, such as skin or lung infections or atopic dermatitis.

TRIAZOLOTHIENOPYRIMIDINE COMPOUND INHIBITORS OF UREA TRANSPORTERS AND METHODS OF USING INHIBITORS

Provided herein are small molecule triazolothienopyrimidine compounds that inhibit urea transport activity of solute transporters, particularly the UT-B transporter. The compounds described herein are useful for increasing solute clearance in states of fluid overload and for treating refractory edema associated with cardiovascular, renal, and metabolic diseases, disorders, and conditions.

Nanomolar potency and metabolically stable inhibitors of kidney urea transporter UT-B

Urea transporters, which include UT-B in kidney microvessels, are potential targets for development of drugs with a novel diuretic ('urearetic') mechanism. We recently identified, by high-throughput screening, a triazolothienopyrimidine UT-B inhibitor, 1, that selectively and reversibly inhibited urea transport with IC50 = 25.1 nM and reduced urinary concentration in mice (Yao et al.J. Am. Soc. Nephrol., in press). Here, we analyzed 273 commercially available analogues of 1 to establish a structure-activity series and synthesized a targeted library of 11 analogues to identify potent, metabolically stable UT-B inhibitors. The best compound, {3-[4-(1,1-difluoroethyl)benzenesulfonyl]thieno[2,3-e][1,2,3]triazolo[1,5-a] pyrimidin-5-yl}thiophen-2-ylmethylamine, 3k, had IC50 of 23 and 15 nM for inhibition of urea transport by mouse and human UT-B, respectively, and ～40-fold improved in vitro metabolic stability compared to 1. In mice, 3k accumulated in kidney and urine and reduced maximum urinary concentration. Triazolothienopyrimidines may be useful for therapy of diuretic-refractory edema in heart and liver failure.

Rhodium(I)-catalyzed addition of arylboronic acids to (benzyl-/ arylsulfonyl)acetonitriles: Efficient synthesis of (Z)-β- sulfonylvinylamines and β-Keto sulfones

An efficient rhodium(I)-catalyzed addition of arylboronic acids to (benzyl-/arylsulfonyl)acetonitrile is described. Novel β-sulfonylvinylamine products are formed in a stereoselective fashion (Z-alkene). Upon hydrolysis, useful β-keto sulfones are obtained with a broad scope of aryl and sulfonyl substituents.